

	A. Total population N=131	B. No oncological disease N=94	C. eGFR < 45 ml/min/1.73m2 N=49
Age (mean ± SD)	71,8 ± 15,4	70,25 ± 16,9	80,71 ± 7,46
Sex=M (%)	64 (48,9%)	41 (43,6%)	21 (42,86%)
Sex=F (%)	67 (51,1%)	53 (56,3%)	28 (57,14%)
PICC	32	23	15
Midline	99	71	34
Dwell time (mean ± SD)	16,7 ± 12,3	16,95 ± 12,5	15,11 ± 8,54
Base line			
Creatinine mg/dl (mean ± SD)	1,23 ± 0,76	1,20 ± 0,8	1,89 ± 0,82
eGFR ml/min/1.73m2 (mean ± SD)	67,52 ± 45,91	73,27 ± 50,2	29,92 ± 10,26
eGFR < 45 ml/min/1.73m2	49 (37,4%)	31 (33%)	
eGFR < 30 ml/min/1.73m2	27 (20,6%)	18 (19,1%)	
Albumine (mean ± SD)	27,52 ± 5,66	28,09 ± 5,8	25,77 ± 5,26
Follow up			
Creatinine (mean ± SD)	1,17 ± 0,87	1,2 ± 0,96	1,78 ± 1,15
eGFR ml/min/1.73m2 (mean ± SD)	70,54 ± 43,98	72,89 ± 47,71	34,63 ± 15,38
eGFR < 15 ml/min/1.73m2	3 (2,3%)	3 (3,13%)	
Prognosis index			
Charlson comorbidity index (mean ± SD)	5,98 ± 3,12	5,24 ± 2,89	6,92 ± 2,28
Beclap score (mean ± SD)	19,68 ± 20,74	17,42 ± 19,65	33,37 ± 23,77
Complications			
Dislodgment (%)	6 (4,6%)	4 (4,3%)	2 (4%)
Catheter related thrombosis (%)	2 (1,5%)	1 (1%)	1 (2%)
Catheter related bloodstream infection (%)	0	0	0
Mortality			
Inpatients	18 (13,7%)	16 (17,02%)	11 (22,45%)
Outpatients	57 (43,51%)	34 (36,17%)	26 (53,06%)
Total	75 (57,3%)	50 (53,19%)	37 (75,51%)

p-value (A vs B)	p-value (A vs C)
0,239	0,5
0,437	0,473
0,438	0,211
0,418	< 0,01
0,19	< 0,01
0,83	
0,787	
0,228	0,032
0,451	< 0,01
0,398	< 0,01
0,679	
0,036	0,029
0,208	< 0,01
0,545	0,024